Page last updated: 2024-08-05 11:07:06

indanes

null

ChEBI ID: 46940

Members (30)

MemberDefinitionRole
1-[2-[2-(2,3-dihydro-1H-inden-5-yloxy)ethoxy]ethyl]-1,2,4-triazole1-[2-[2-(2,3-dihydro-1H-inden-5-yloxy)ethoxy]ethyl]-1,2,4-triazole
1-indanolindan-1-ol
2-(2,3-dichlorophenoxy)-N-(2,3-dihydro-1H-inden-5-yl)acetamide2-(2,3-dichlorophenoxy)-N-(2,3-dihydro-1H-inden-5-yl)acetamide
5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarbohydrazide5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarbohydrazide
5-(tert-butyl)-N-(2,3-dihydro-1H-inden-2-yl)-2-methyl-3-furamide5-(tert-butyl)-N-(2,3-dihydro-1H-inden-2-yl)-2-methyl-3-furamide
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime
acetyl tert-butyl dimethylindan4-Acetyl-6-tert-butyl-1,1-dimethylindane
amidonalAprindine hydrochloride
aprindineaprindine
enrasentanA member of the class of indanes that is 2,3-dihydro-1H-indene which is substituted by a 1,3-benzodioxol-5-yl group, carboxy group, 2-(2-hydroxyethoxy)-4-methoxyphenyl group and a propoxy group at positions 1S, 2R, 3S and 5, respectively. It is an orally active mixed endothelin A/B receptor antagonist with a 100-fold greater affinity for the endothelin A receptor. The drug was being developed by GSK for the treatment of congestive heart failure and pulmonary hypertension (clinical trials discontinued).enrasentan
GDC-0879A member of the class of pyrazoles that is 1-(2-hydroxyethyl)pyrazole carrying additional 4-pyridyl and 1-(hydroxyimino)indan-5-yl substituents at positions 3 and 4 respectively.GDC-0879
ici 1185511-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)-2-butanol
ici 118551An indane substituted at position 7 by a methyl group and at position 4 by a 3-(isopropylamino)-2-hydroxybutoxy group (the 2R,3S-diastereomer).ICI 118551
indacaterolA monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary disease.indacaterol
indanAn ortho-fused bicyclic hydrocarbon consisting of a benzene ring fused to a cyclopentane ring; a high-boiling (176 (o)C) colourless liquid.indane
indanazolineindanazoline
indatraline(1R,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine
N-(2,3-dihydro-1H-inden-5-yl)-2-[(2-nitro-3-pyridinyl)oxy]acetamideN-(2,3-dihydro-1H-inden-5-yl)-2-[(2-nitro-3-pyridinyl)oxy]acetamide
N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamideN-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamide
N-(2,3-dihydro-1H-inden-5-yl)-2-methyl-3-nitrobenzamideN-(2,3-dihydro-1H-inden-5-yl)-2-methyl-3-nitrobenzamide
N-(2,3-dihydro-1H-inden-5-yl)-5-methyl-2-pyrazinecarboxamideN-(2,3-dihydro-1H-inden-5-yl)-5-methyl-2-pyrazinecarboxamide
N-[2-(2-methoxyphenoxy)ethyl]-2,3-dihydro-1H-indene-5-carboxamideN-[2-(2-methoxyphenoxy)ethyl]-2,3-dihydro-1H-indene-5-carboxamide
pevonedistatpevonedistat; sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester
pevonedistatA pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.pevonedistat; sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester
quadrangularin aAn indane-derived stilbenoid that is a homodimer obtained by cyclodimerisation of resveratrol.quadrangularin A
ramelteonN-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide
rasagilineAn indane that consists of 1-aminoindane bearing an N-propargyl substituent. A selective, irreversible monoamine oxidase-B inhibitor.rasagiline
tolindatetolindate
tv3326Ladostigil
u 991945,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine

Research

Studies (2,661)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-1990426 (16.01)18.7374
1990's384 (14.43)18.2507
2000's514 (19.32)29.6817
2010's1,049 (39.42)24.3611
2020's288 (10.82)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials303 (10.53%)5.53%
Reviews332 (11.54%)6.00%
Case Studies108 (3.75%)4.05%
Observational12 (0.42%)0.25%
Other2,123 (73.77%)84.16%